Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 15

Sponsor: University of California, Irvine

Location: Chao Family Comprehensive Cancer Center, University of California, Irvine Orange California

Summary

This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritoneal (PMP) secondary to appendiceal mucinous neoplasms (AMNs).

Eligibility Criteria

Key Inclusion Criteria (complete details available in protocol): * Patients with clinical diagnosis of PMP secondary to presumed AMNs with recurrent/refractory disease s/p CRS/HIPEC, unresectable disease, or without planned CRS/HIPEC * Age ≥18 years * ECOG performance status ≤2 Key Exclusion Criteria (complete details available in protocol): * Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS/HIPEC * Patients currently taking metformin for another medical indication * Patients with a prior adverse event to administration of metformin

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07693452). StuddyBuddy aggregates publicly available trial information.